Clover Biopharmaceuticals, Ltd. (02197.HK)

Clover Biopharmaceuticals Ltd. engages in the research and development of biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 243 full-time employees. The company went IPO on 2021-11-05. The Company’s products and candidates include Respiratory Syncytial Virus (RSV) Vaccine (SCB-1019), seasonal quadrivalent influenza vaccine AdimFlu-S, SCB-219M, COVID-19 Vaccine and others. The firm leverages the Trimer-Tag technology platform to conduct research and development (R&D) for innovative vaccines that can fulfill unmet need, with a focus on building a respiratory vaccine franchise and establishing a presence in the pediatric vaccine market. The Trimer-Tag is a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets. The firm conducts its business in the domestic and overseas markets.